Latest news and press releases about Imunon, Inc. (IMNN): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Imunon, Inc. is a clinical-stage biotechnology company dedicated to the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. The company's pipeline features GEN-1, a DNA-based immunotherapy specifically designed for the localized treatment of ovarian cancer, and ThermoDox, a proprietary heat-activated liposomal formulation of doxorubicin, currently in development for various cancer indications.
Price
| Price | $1.41 |
| Market Cap | $6M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 1.77 |
| EV / EBITDA | -0.54 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -314.89% |
| Return on Invested Capital | -122.18% |
| Return on Assets | -98.17% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: AEON · BOLT · CING · CLRB · COCP · DWTX · EVGN
Explore sector: Healthcare · Biotechnology
More sections of IMNN: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks